Comprehensive 15-page eyeforpharma briefing featuring interviews with 19 senior clinical trial leaders, best patient centricity practices and executive action points from Eli Lilly, Genzyme, National Breast Cancer Coalition, CTTI, PCORI, UCB, Cancer Treatment Centers of America, Michael J. Fox Foundation and more
This white paper explores how medical imaging systems can improve sites' overall experience in an imaging trial, how processes designed to support sites ultimately benefit all trial participants, and how site staff burdened with fewer manual processes can spend more time with patients, get patients on therapy sooner and deliver results to sponsors faster.
Barnett offers training and recourses for Clinical Research Professionals. Included are several new training programs, all designed with a practical, job-focused purpose and the needs of our learners in mind. New training offerings include In-Person Seminars, Web-Based 30-hour Certification Programs, Web Seminars, and Publications.
Hypromellose (HPMC) capsules were originally formulated with a secondary gelling agent. This agent can delay dissolution in some circumstances and lead to unwanted issues during product development. In this article, we discuss the rationale for developing Capsugel’s Vcaps® Plus capsules without a gelling agent. We also describe how these capsules – now in use at many major pharmaceutical companies to encapsulate their existing over-the-counter [OTC] products and New Chemical Entities [NCEs] – can optimize product performance and improve product stability, as well as reduce development timelines.
If it’s true that two heads are better than one, then three, four or heck, maybe 304 heads working in partnership must be even better, right? Well, it depends. Building partnerships that are both smart and sustainable takes planning, patience and perseverance. In this whitepaper, Merge eClinical’s President Zaher El-Assi shares lessons learned and the core practices his company uses to forge long-term partnerships that produce value for both companies that goes beyond the traditional buy-sell relationship.
This whitepaper discusses the importance of observational research and patient registries in evidence generation. The modern healthcare environment is a mosaic of stakeholders, each with remarkably different demands for data addressing product attributes. These often conflicting perspectives require access to a portfolio of interventional and observational research designs sub-serving different objectives … Increasingly central is the inclusion of observational studies, including registries, which provide insights missing from traditional interventional studies encountered in the course of drug development.
Are you a clinical research professional looking for training resources? Barnett's July 2014 - January 2015 Course & Publications Catalog offers a variety of training programs. These programs are designed to maximize learner engagement and include the following: In-Person and Web-Based training courses, custom programs and services, eLearning, and Publications.
Dr. Philip Sager, consultant for Biomedical Systems, explores several related topics to discuss the impact of medicines on Blood Pressure (BP), and the role BP plays in the development and testing of compounds. This whitepaper explains challenges of using epidemiologic data for risk assessment; the cardiovascular risk from BP changes with long-term therapy; the precision of measurement techniques; developing an assessment process from nonclinical evaluation through Phase III monitoring; mitigating risk; and the use of ambulatory BP monitoring (ABPM) in clinical trials.